5-HTP for Anxiety

Verdict: Weak, dated evidence; not a proven anxiety treatment

The evidence that 5-HTP relieves anxiety is weak and outdated, resting on a handful of small trials from 1985 to 2004 with mixed results. It should not be regarded as a proven treatment for anxiety disorders, and it carries real safety concerns.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

This claim earns a Weak (C) grade because the entire human evidence base is just four small, old randomized trials and none provide convincing proof for clinical anxiety. The most positive result is narrow: a single 200 mg dose blunted carbon-dioxide-induced panic in panic disorder patients but did nothing in healthy volunteers (PMID 12559480). A parallel challenge study using CCK-4 failed to reach significance (19% vs 44% panic, p=0.13), with only a non-significant trend and an effect seen in women alone (PMID 15260907).

Crucially, these are acute panic-provocation experiments, not tests of sustained, real-world anxiety treatment. The only trials of ongoing therapy are weak: 5-HTP was clearly outperformed by the drug clomipramine on every measure (PMID 3312397), and the remaining study was an uncontrolled open-label trial of just 10 people (PMID 3157732). Effect sizes were generally not reported, sample sizes were tiny, and no modern RCTs exist.

No health authority or major clinic endorses 5-HTP for anxiety. The US FDA states it cannot determine that 5-HTP and related compounds are safe for use as dietary supplements, reflecting their link to the 1989 eosinophilia-myalgia syndrome outbreak, and EFSA has authorized no health claims. Mainstream clinics (Mayo, Cleveland Clinic, Harvard, NIH ODS) do not address it for this use. Serotonin-syndrome risk when combined with SSRIs, SNRIs, MAOIs, or triptans is a further reason for caution.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
75%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients
PMID: 12559480 2002 RCT (double-blind) n = 48
Finding: 5-HTP significantly reduced panic reaction in panic disorder patients vs placebo; no effect in healthy volunteers (no p-value in abstract).
View on PubMed
The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers
PMID: 15260907 2004 RCT (double-blind) n = 32
Finding: Nonsignificant lower panic rate (19% 5-HTP vs 44% placebo, p=0.13); trend for lower intensity (p=0.08); protective effect in females only.
Government
View on PubMed
Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-HTP, clomipramine and placebo
PMID: 3312397 1987 RCT (double-blind) n = 45
Finding: 5-HTP showed only moderate symptom reduction; clomipramine significantly outperformed 5-HTP on all measures (no p-value in abstract).
🟠 Limited quality
View on PubMed
L-5-hydroxytryptophan in the treatment of anxiety disorders
PMID: 3157732 1985 RCT (open-label) n = 10
Finding: Significant reduction in anxiety observed across three scales (no p-value, no control group, n=10).
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA cannot determine that oral dosage forms of L-Tryptophan and related compounds such as L-5-hydroxytryptophan can be safely used as dietary supplements. source↗
L4d TW TFDA / 衛福部
Against
5-HTP在台灣並非合法的保健食品(食品)原料;色胺酸(L-tryptophan)則為合法之食品營養補充劑成分。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-5-htp-001 繁體中文版 →